US Patent

US12194150 — Levodopa dosing regimen

Method of Use · Assigned to Amneal Pharmaceuticals LLC · Expires 2041-12-21 · 16y remaining

Vulnerability score 58/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects oral dosing regimens of controlled release levodopa compositions for treating patients with Parkinson's disease.

USPTO Abstract

The invention provides oral dosing regimens of controlled release levodopa compositions for use in treating patients with Parkinson's disease.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-219 — Sinemet Cr
U-219 — Sinemet Cr
U-219 — Sinemet Cr
U-219 — Sinemet Cr

Patent Metadata

Patent number
US12194150
Jurisdiction
US
Classification
Method of Use
Expires
2041-12-21
Drug substance claim
No
Drug product claim
No
Assignee
Amneal Pharmaceuticals LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.